Martin Vogelbaum - Net Worth and Insider Trading

Martin Vogelbaum Net Worth

The estimated net worth of Martin Vogelbaum is at least $15,134 dollars as of 2024-11-13. Martin Vogelbaum is the Director of Cara Therapeutics Inc and owns about 44,988 shares of Cara Therapeutics Inc (CARA) stock worth over $15,134. Details can be seen in Martin Vogelbaum's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Vogelbaum has not made any transactions after 2022-09-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Martin Vogelbaum

Martin Vogelbaum Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Vogelbaum owns 4 companies in total, including Cara Therapeutics Inc (CARA) , Rocket Pharmaceuticals Inc (RCKT) , and NephroGenex Inc (NRXGQ) among others .

Click here to see the complete history of Martin Vogelbaum’s form 4 insider trades.

Insider Ownership Summary of Martin Vogelbaum

Ticker	Comapny	Transaction Date	Type of Owner
CARA	Cara Therapeutics Inc	2022-09-14	director
RCKT	Rocket Pharmaceuticals Inc	2015-02-17	director
NRXGQ	NephroGenex Inc	2014-05-15	director
		2003-06-19	director

Martin Vogelbaum Latest Holdings Summary

Martin Vogelbaum currently owns a total of 1 stock. Martin Vogelbaum owns 44,988 shares of Cara Therapeutics Inc (CARA) as of September 14, 2022, with a value of $15,134.

Latest Holdings of Martin Vogelbaum

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CARA	Cara Therapeutics Inc	2022-09-14	44,988	0.34	15,134

Holding Weightings of Martin Vogelbaum

Martin Vogelbaum Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Vogelbaum has made a total of 3 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 10,800 shares on September 14, 2022, which brought Martin Vogelbaum around $111,024.

Insider Trading History of Martin Vogelbaum

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Vogelbaum Trading Performance

GuruFocus tracks the stock performance after each of Martin Vogelbaum's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Martin Vogelbaum is 1.01%. GuruFocus also compares Martin Vogelbaum's trading performance to market benchmark return within the same time period. The performance of stocks bought by Martin Vogelbaum within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Martin Vogelbaum's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Martin Vogelbaum

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	49.19
Relative Return to S&P 500(%)	47.22

Martin Vogelbaum Ownership Network

Ownership Network List of Martin Vogelbaum

No Data

Ownership Network Relation of Martin Vogelbaum

Martin Vogelbaum Owned Company Details

What does Cara Therapeutics Inc do?

Who are the key executives at Cara Therapeutics Inc?

Martin Vogelbaum is the director of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .

Cara Therapeutics Inc (CARA) Insider Trades Summary

Over the past 18 months, Martin Vogelbaum made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 5,476 shares made by Joana Goncalves , and a net sale of 5,236 shares made by Scott Terrillion .

In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.

Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cara Therapeutics Inc Insider Transactions

No Available Data

What does Rocket Pharmaceuticals Inc do?

Who are the key executives at Rocket Pharmaceuticals Inc?

Martin Vogelbaum is the director of Rocket Pharmaceuticals Inc. Other key executives at Rocket Pharmaceuticals Inc include Chief Medical Officer Mark Andrew White , See Remarks John Militello , and General Counsel Martin Wilson .

Rocket Pharmaceuticals Inc (RCKT) Insider Trades Summary

Over the past 18 months, Martin Vogelbaum made no insider transaction in Rocket Pharmaceuticals Inc (RCKT). Other recent insider transactions involving Rocket Pharmaceuticals Inc (RCKT) include a net sale of 22,492 shares made by John Militello , a net sale of 48,601 shares made by Gaurav Shah , and a net sale of 582,989 shares made by Gotham Makker .

In summary, during the past 3 months, insiders sold 19,727 shares of Rocket Pharmaceuticals Inc (RCKT) in total and bought 0 shares, with a net sale of 19,727 shares. During the past 18 months, 779,172 shares of Rocket Pharmaceuticals Inc (RCKT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 779,172 shares.

Rocket Pharmaceuticals Inc (RCKT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rocket Pharmaceuticals Inc Insider Transactions

No Available Data

What does NephroGenex Inc do?

Who are the key executives at NephroGenex Inc?

Martin Vogelbaum is the director of NephroGenex Inc. Other key executives at NephroGenex Inc include director & Chief Executive Officer Pierre Legault , director & 10 percent owner Richard J Markham , and 10 percent owner Joshua Ruch .

NephroGenex Inc (NRXGQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NephroGenex Inc (NRXGQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NephroGenex Inc (NRXGQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NephroGenex Inc (NRXGQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

NephroGenex Inc Insider Transactions

No Available Data

What does ARCA biopharma Inc do?

Who are the key executives at ARCA biopharma Inc?

Martin Vogelbaum is the director of ARCA biopharma Inc. Other key executives at ARCA biopharma Inc include 10 percent owner & other: See Footnote 1 Funicular Funds, Lp , other: See Footnote 1 Funicular Fund, Lp , and other: See Remarks Jacob Ma-weaver .

ARCA biopharma Inc (ABIO) Insider Trades Summary

Over the past 18 months, Martin Vogelbaum made no insider transaction in ARCA biopharma Inc (ABIO). Other recent insider transactions involving ARCA biopharma Inc (ABIO) include a net purchase of 634,678 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of ARCA biopharma Inc (ABIO) in total and bought 485 shares, with a net purchase of 485 shares. During the past 18 months, 0 shares of ARCA biopharma Inc (ABIO) were sold and 52,890 shares were bought by its insiders, resulting in a net purchase of 52,890 shares.

ARCA biopharma Inc (ABIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARCA biopharma Inc Insider Transactions

No Available Data

Martin Vogelbaum Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Vogelbaum. You might contact Martin Vogelbaum via mailing address: 675 Almanor Ave, Sunnyvale Ca 94085.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.